Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT07249905 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Waldenström Macroglobulinemia (WM)
DLBCL - Diffuse Large B Cell Lymphoma
PMBCL
HGBCL
FL Lymphoma
Lymphoplasmacytic Lymphoma
Follicular Lymphoma (FL)

Interventions

DRUG: MDX2003

Sponsor

ModeX Therapeutics, An OPKO Health Company